These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34860418)

  • 1. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
    Yurdaydin C; Keskin O; Yurdcu E; Çalişkan A; Önem S; Karakaya F; Kalkan Ç; Karatayli E; Karatayli S; Choong I; Apelian D; Koh C; Heller T; Idilman R; Bozdayi AM; Glenn JS
    Hepatology; 2022 Jun; 75(6):1551-1565. PubMed ID: 34860418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
    Koh C; Canini L; Dahari H; Zhao X; Uprichard SL; Haynes-Williams V; Winters MA; Subramanya G; Cooper SL; Pinto P; Wolff EF; Bishop R; Ai Thanda Han M; Cotler SJ; Kleiner DE; Keskin O; Idilman R; Yurdaydin C; Glenn JS; Heller T
    Lancet Infect Dis; 2015 Oct; 15(10):1167-1174. PubMed ID: 26189433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.
    Canini L; Koh C; Cotler SJ; Uprichard SL; Winters MA; Han MAT; Kleiner DE; Idilman R; Yurdaydin C; Glenn JS; Heller T; Dahari H
    Hepatol Commun; 2017 Jun; 1(4):288-292. PubMed ID: 29404459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis D: an unmet medical need.
    Caviglia GP; Rizzetto M
    Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials.
    Lamers MH; Kirgiz ÖÖ; Heidrich B; Wedemeyer H; Drenth JP
    Antivir Ther; 2012; 17(6):1029-37. PubMed ID: 22892440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
    Asselah T
    Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
    Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E;
    AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
    Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
    Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
    Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
    N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN; Capparelli EV; McIlleron H; Gerhart JG; Dumond JB; Kashuba ADM; Denti P; Gonzalez D
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
    Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
    AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
    Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.